Ranbaxy slides after US FDA flags new GMP concerns
This article was originally published in Scrip
Executive Summary
Shares of Ranbaxy declined by more than 5% on Indian bourses after the firm said that a recent inspection by the US FDA had identified certain good manufacturing practice (GMP) deficiencies at its active pharmaceutical ingredients (API) site in Toansa, India.